TraceLink unveils industry’s first Compliance and Digital Information Platform for pharmacies with EU FMD requirements
Application "addresses a critical information gap that has existed for decades between pharmaceutical companies, pharmacists and patients."
TraceLink has unveiled an industry first: an integrated Compliance and Digital Information Platform for pharmacies with EU Falsified Medicines Directive (FMD) requirements.
The new mobile and web-based application enables any pharmacy in the EU to easily comply with verification and decommissioning requirements under the FMD while simultaneously delivering a real-time dashboard for business insights on medicine scans, expiry dates, dispensation trends, product inventory and more. The new platform was revealed at NEXUS 17 in Barcelona during the opening keynote session by TraceLink president and CEO, Shabbir Dahod.
The new Pharmacy Compliance and Digital Information Platform provides a single destination for pharmacies to meet their EU FMD requirements, which take effect in February 2019. Pharmacists who use the application will also benefit from user-friendly dashboard analytics that provide valuable insights from all transaction information that is captured within the application.
Pharmacists can also “opt in” to a service within the app that links them to participating pharmaceutical manufacturers, paving the way for a new digital communication channel designed to enhance the information-sharing between pharmaceutical companies and the healthcare providers who dispense their medications. Once they opt in, pharmacists will be able to receive specific and contextual pharmaceutical product information directly from the manufacturer – including details about indications, usage, best practices for product administration, and potential warnings and precautions - empowering them to deliver a more engaging and informative consultation as they dispense medicines to patients.
“TraceLink has broken new ground with this application, addressing a critical information gap that has existed for decades between pharmaceutical companies, pharmacists and patients,” said Dahod. “Our unique approach of connecting the entire pharmaceutical supply chain on an interoperable network makes TraceLink the only company capable of offering this type of solution and facilitating a new era of real-time information sharing that will transform how the industry provides care to patients. This is the first in a series of steps we are taking to augment our effort of eliminating counterfeit drugs from the global marketplace with applications that deliver tangible and meaningful value to an industry that serves hundreds of millions of people who depend on prescription medications to improve their health.”
TraceLink’s new Pharmacy Compliance and Digital Information Platform merges EU FMD compliance capabilities with real-time insights into pharmaceutical products, offering EU pharmacists the ability to
All services within the Pharmacy Compliance and Digital Information Platform will be provided by TraceLink via its secure Life Sciences Cloud where pharmacists can be assured of the confidentiality and anonymous nature of their dispensing information.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance